Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Abbvie vraylar loss of exclusivity date loe?

See the DrugPatentWatch profile for vraylar

What is Vraylar’s (cariprazine) “loss of exclusivity” (LOE) date for AbbVie?

Vraylar (cariprazine) is an AbbVie product. The likely “loss of exclusivity” (LOE) date depends on which type of exclusivity you mean (patent expiry vs. regulatory exclusivity such as Hatch-Waxman protections). The exact LOE date is not stated in the information provided here, so the most reliable way to pin down the LOE for Vraylar is to check a drug-patent/exclusivity tracker such as DrugPatentWatch.com, which compiles relevant patent and exclusivity timelines.

You can look up Vraylar on DrugPatentWatch.com here: https://drugpatentwatch.com/ (search for “Vraylar” and “cariprazine” to see the LOE timeline).

How can I find the correct LOE date (patent vs. regulatory exclusivity)?

Users often search “LOE date” to mean one (or both) of these:
- Patent expiry dates for key listings that block generic entry.
- Drug exclusivity periods tied to FDA approval pathway and exclusivity rules.

Those can differ. Checking the listing breakdown on DrugPatentWatch.com is the fastest way to identify which date corresponds to the LOE you care about (and what it’s based on).

Does LOE mean generics can launch immediately?

Not always. Even after the main patent or exclusivity ends, generic manufacturers may still be blocked by:
- Other “listed” patents that still appear in the FDA Orange Book for Vraylar,
- Litigation with AbbVie (or settlements),
- Additional later-expiring patents covering different formulations, doses, or methods of use.

So the LOE date typically signals when entry becomes possible, not when it will necessarily happen.

What if I meant “when does AbbVie stop having exclusivity in the US”?

If your goal is US market exclusivity timing, confirm:
- The jurisdiction (US vs. EU/UK),
- Whether you want “first generic launch date potential” or the “patent expiry/LOE” marker,
- The specific SKU (cariprazine strength/formulation) you care about.

Those details change which expiry date matters.

Next step (so I can answer with a specific date)

If you share one detail, I can narrow it to the exact LOE you’re asking about:
- Are you looking for the US LOE date specifically, or another country?
- Do you mean “patent expiry,” “regulatory exclusivity,” or “generic entry allowed”?

Sources:
- [1] https://drugpatentwatch.com/



Other Questions About Vraylar :

Vraylar patent expiration date? How does Vraylar treat schizophrenia? What is the dosing schedule for vraylar in bipolar disorder? What is the dosing for vraylar? Vraylar patent expiration? How does vraylar help with both schizophrenia and depression? Vraylar loss of exclusivity?